Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Diffuse, aggressive non-Hodgkin's lymphomas (NHL) encompass several subtypes with varying clinical behaviors.
• Accurate immunologic phenotyping is crucial for understanding NHL pathogenesis and guiding treatment strategies.

Purpose of the Study:

• To determine the immunologic phenotypes of a cohort of diffuse, aggressive non-Hodgkin's lymphomas.
• To assess the utility of immunotyping in classifying these lymphomas and its potential prognostic impact.

Main Methods:

• Utilized a battery of immunologic and cytochemical techniques to phenotype 59 cases of diffuse, aggressive NHL.
• Excluded distinct entities like Burkitt's lymphoma and lymphoblastic lymphoma.
• Employed monoclonal anti-T cell antibody staining and spontaneous E-rosette formation for T-cell characterization.

Main Results:

• Immunotype was determined in 97% of cases: 53% B-cell, 42% peripheral T-cell, 1% true histiocytic, and 2% "null cell."
• Observed a higher frequency of peripheral T-cell lymphomas than previously reported in American series.
• All B-cell lymphomas expressed monoclonal surface immunoglobulin; T-cell lymphomas showed varied phenotypes (helper/suppressor).

Conclusions:

• Immunotyping is highly successful in diffuse, aggressive NHL, revealing a notable proportion of peripheral T-cell lymphomas.
• Enzyme cytochemistry showed limited correlation with immunotype.
• Immunotype alone did not demonstrate an independent prognostic effect on clinical outcomes in this study.